Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index (BMI) alone in assessing cardiovascular (CV) risk in people with HIV (PWH). The study […]
Theratechnologies presented data at CROI 2025 highlighting BMI's limitations in assessing cardiovascular risk in people with HIV. The VAMOS study demonstrated that excess visceral abdominal fat (EVAF) is a key driver of cardiovascular risk, even in individuals with normal or overweight BMI. The study suggests that healthcare providers should incorporate screening for EVAF, such as measuring waist circumference, to better identify at-risk individuals.
